Showing results (351-360 of 408) with videos related to

Sort By:
Pageof 41
Journal of Spinal Disorders & Techniques|February 8, 2006
Surgical decision making for unstable thoracolumbar spine injuries: results of a consensus panel review by the Spine Trauma Study GroupAlexander R Vaccaro, Moe R Lim, R John Hurlbert, et al.
Clinical Pharmacology and Therapeutics|July 10, 2014
Accelerated access to innovative medicines for patients in needL G Baird, R Banken, H-G Eichler, et al.
BMJ Global Health|March 28, 2024
Estimation of country-specific tuberculosis resistance antibiograms using pathogen genomics and machine learningAvika Dixit, Luca Freschi, Roger Vargas, et al.
Scientific Reports|February 14, 2018
The NLRP3 Inflammasome May Contribute to Pathologic Neovascularization in the Advanced Stages of Diabetic RetinopathyShyam S Chaurasia, Rayne R Lim, Bhav H Parikh, et al.
Molecular Cancer Therapeutics|December 3, 2009
The antiproliferative activity of the heat shock protein 90 inhibitor IPI-504 is not dependent on NAD(P)H:quinone oxidoreductase 1 activity in vivoMark Douglas, Alice R Lim, James R Porter, et al.
Drug Metabolism and Disposition: the Biological Fate of Chemicals|February 12, 2015
Systemic exposure to and disposition of catechols derived from Salvia miltiorrhiza roots (Danshen) after intravenous dosing DanHong injection in human subjects, rats, and dogsMeijuan Li, Fengqing Wang, Yühong Huang, et al.
Journal of Refractive Surgery (Thorofare, N.J. : 1995)|February 14, 2017
Conventional Versus Inverted Side-cut Flaps for Femtosecond Laser-Assisted LASIK: Laboratory and Clinical EvaluationVishal Jhanji, Tommy C Y Chan, Wai Ying Li, et al.
Proceedings of the National Academy of Sciences of the United States of America|May 17, 2022
DNA methylation clocks for dogs and humansSteve Horvath, Ake T Lu, Amin Haghani, et al.
Biorxiv : the Preprint Server for Biology|February 23, 2026
Nutrient microenvironments reprogram RPE metabolismRayne R Lim, Emily Zhao, Daniel T Hass, et al.
Annals of Oncology : Official Journal of the European Society for Medical Oncology|March 10, 2011
Phase I and pharmacodynamic study of an orally administered novel inhibitor of histone deacetylases, SB939, in patients with refractory solid malignanciesW P Yong, B C Goh, R A Soo, et al.
Pageof 41